Neuraxpharm and Pharmathen enter into strategic co-development agreement to develop long-acting injectable therapies

New therapies will offer patients greater choice and flexibility in controlling CNS disorders

BARCELONA, Spain, DÜSSELDORF, Germany, and ATHENS, Greece, December 12, 2024 /PRNewswire/ — Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Pharmathen, one of the largest pharmaceutical companies in Greece and leader in the development and supply of long-acting injectable (LAI) therapies, announces a strategic alliance to co-develop new long-acting injectable therapies in the field of psychiatry under Pharmathen’s Long-Acting Therapeutic Technologies (LATT) program.

Under the terms of this agreement, Neuraxpharm will have exclusive rights to market these therapies in Europe and countries outside Europe where the group is directly present, while Pharmathen will have exclusive rights for North America and all other countries not covered. by Neuraxpharm.

Pharmathen’s LATT program uses its proprietary technologies to replace traditionally available short-acting dosage forms, such as tablets or injectables, with longer-acting injectable therapies to address the unmet needs of prescribers and patients. LATT allows for better long-term symptom control, provides greater patient compliance and greater convenience in patient treatment.

Pharmathen, with proven experience in developing and launching LAI products globally, will be the technology, manufacturing and supply partner. Neuraxpharm, with its proven expertise in commercializing SNC products in Europe, will register and market the products across Europe and other direct Neuraxpharm markets. Neuraxpharm is now established in more than 20 European countries, with subsidiaries in Latin America, the Middle East and a global network of distributors.

Commenting, Dr. Jörg-Thomas Dierks, CEO, said: “Today’s announcement reflects our continued commitment to bringing innovative solutions to CNS patients in Europe and beyond. These are well-established therapies, but we are bringing them to market in a new format, which will provide patients with greater flexibility and control in how they manage. often difficult conditions. »

Dimitris Kadis, CEO of Pharmathen Group, said: “At Pharmathen, our mission is to improve patients’ lives through innovation and quality. This collaboration is an important step toward achieving this goal by improving access, convenience and choice for our patients as we bring our long-acting therapeutic technology products to more people. CNS prescribers and patients worldwide.

About the Neuraxpharm group

Neuraxpharm is a leading European specialty pharmaceutical company in the treatment of the central nervous system (CNS), including psychiatric and neurological disorders. She has a unique understanding of the CNS market built over 35 years.

Neuraxpharm constantly innovates, with new products and solutions to address unmet patient needs and expands its portfolio through its pipeline, partnerships and acquisitions.

The company has approximately 1,000 employees and develops and markets CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East and globally through partners in more than 50 country. Neuraxpharm is supported by funds advised by Permira.

Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain.

For more information, please visit https://www.neuraxpharm.com

About Pharmathen

Founded in 1969, Pharmathen has grown into one of the largest vertically integrated companies developing innovative pharmaceutical formulations. With high-level research and development in cutting-edge technologies, Pharmathen today works on one of the most complex and advanced portfolios, consisting of more than 40 products, focusing on sustained-release injectable products. , controlled release formulations and ophthalmic products. Its products are manufactured at the company’s facilities in Greece, which are approved by the United States Food and Drug Administration (FDA) and the European Union. Pharmathen’s highly diversified product portfolio, with more than 90 commercial products, is sold to 250 cooperating customers, providing access to patients in more than 90 countries around the world.

For more information, please visit

Show original content: